

DAFTAR PUSTAKA

1. *International Agency for Research on Cancer (IARC) / WHO. (2012). GLOBOCAN 2012: Estimated cancer incidence, mortality, and prevalence world wide in 2012.*
2. World Health Organization. *International Agency Research for Research on Cancer. Latest world cancer statistics Global cancer burden rises to 14.1 million new cases in 2012: Marked increase in breast cancers must be addressed.* IARC. 2013
3. American Cancer Institute. *Breast cancer fact and figure 2015.* .American Cancer Society, Surveillance Research, 2015
4. Kementerian Kesehatan RI. (2013). Riset Kesehatan Dasar (RISKESDAS). Jakarta: Badan Litbang Kemenkes RI.
5. Kementerian Kesehatan RI. (2015). Buletin Jendela Data & informasi kesehatan, semester 1, 2015
6. Harahap WA, Arisanty D, Khambri D, Yanwirasti, Mubarika S. Metilasi Promoter Gen BRCA1 dan Pengaruhnya terhadap Karakteristik Kanker Payudara Premenopause sporadik Etnis Minang, CDK-226/ vol. 42 no. 3, th. 2015.
7. Falck AK, Fernö M, Bendahl PO, Rydén L. St Gallen. *Molecular subtypes in primary breast cancer and matched lymph node metastases – aspects on distribution and prognosis with luminal A tumours: result from a prospective randomized trial.* BMC cancer. 2013; 13: 558: 1–10
8. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ. *Personalizing the treatment of women with early breast cancer: highlight of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.* Annals of Oncology. 2013; 00: 1-1
9. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. *Molecular portraits of human breast tumours.* Nature 2000.;406(6797):747-52.
10. Akslen LA, Molecular classification of breast cancer 5-2015. di kutip dari: <http://legeforeningen.no/Global/Fagmedisinske%20foreninger/Den%20norske%20patologforening/molecular%20classification%202015.pdf>. Diakses Pada 4 oktober 2016
11. Suyatno, Pasaribu ET. Bedah onkologi diagnostic dan terapi. Jakarta: Sagung Seto; 2010
12. Tjakra WM, editor. Panduan Penatalaksanaan Kanker Solid PERABOI. Jakarta: Sagung Seto; 2010.

13. Khambri D, 2015 evaluasi prevalensi ekspresi AR dan hubungannya pada karsinoma payudara sub tipe Luminal A, Luminal B, HER2 dan TNBC serta faktor prognosis lainnya. Padang: Disertasi, Universitas Andalas: 2015
14. Burstein HJ, 2005. *The distinctive nature of HER2-positive breast cancers*, *n engl j med*. 353;16
15. Rubin L, Yarden Y. *The basic biology of HER2*. 2001. *Ann oncol*, Vol. Supp 1, pp. S3-8
16. Aryandono T. Faktor prognosis kanker payudara *operable* di Yogyakarta. Yogyakarta: Disertasi, Universitas Gajah Mada; 2006:188.
17. Bilous M, Ades C, Armes J, Bishop J, Brown R, Cooke B, Cummings M, Farshid G, Field A, Morey A, McKenzie P, Raymond W, Robbins P, Tan L, 2003. *Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancer as part of the HER2000 International Study*. *The Breast* 12:92-98.
18. Colomer R, 1998. *Relationship of Tissue and Circulating erb-B2 with prognosis in primary breast cancer. Symposium Proceeding :Changes in the Treatment Of Breast Cancer*. Chesire, Gardiner-Caldwell Communications Ltd:105- 108.
19. Donegan WL, 1997. *Tumor- related prognostic factors for breast cancer*. *CA Cancer J. Clin.* 47:28-51.
20. Toikkanen S, Helin H, Isola J, Joensuu H, 1992. *Prognostic significance of HER-2 oncoprotein expression in breast cancer. A 30-year follow-up*. *J. Clin. Oncol* 10:1044-48.
21. Iqbal N, 2014, *Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications*. *Molecular Biology International*. Hindawi. 2014
22. Trastuzumab. Jangka Panjang Efektif sebagai Terapi Adjuvan dalam Kombinasi Kemoterapi. *CDK-194/ vol. 39 no. 6, th. 2012*
23. Hilda Wong, et al. *Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+++ Metastatic Breast Cancer*. *The Oncologist*, Vol. 16, pp. 1535–1546
24. DeSantis, CE et al. *Research Article International Variation in Female Breast Cancer Incidence and Mortality Rates*. *Cancer Epidemiology, Prevention and biomarker*. 2015
25. Ramli M, Tjindarbumi D, Watanabe S, Darwis I, Sakamoto G, Cornain S, et al. *Clinicopathological aspects of Breast Cancer: a joint study between Indonesia and J Japan*. *Med J Indonesia* 1995;4:148-53.

26. Shenoy RK, Nileshwar A, 2014. Buku Ajar Ilmu Bedah, jilid satu. Faktor Risiko yang Dapat Diidentifikasi. Hal 412-413.
27. Ramli.M ; *update Breast Cancer Management Diagnostic and Treatment*, Majalah Kedokteran Andalas, Vol. 38, No. Supl. 1, Agustus 2015.
28. American Joint Committee on Cancer. Breast cancer staging, ed 7th. Dikutip dari <https://cancerstaging.org/referencestools/quickreferences/Documents/BreastMedium.pdf>. Diakses 30 September 2016
29. BL, Iglehart DJ. *Diseases of the breast. Sabiston Textbook of Surgery*. Ed 18th. Saunders/Elsevier. 2008; p 868-945
30. Kelly HK, Lisa NA, Edward Copeland III M, Kirby BI. *The Breast. Schwartz's Principles of Surgery Ninth Edition*. USA: The McGraw-Hill Companies. Inc. 2010;
31. Carey LA, Perou CN, Livasy CA et al. 2006. *Race breast cancer subtype and survival in the Carolina*. Breast Cancer Study (J) JAMA;295 (21):2942-2502
32. Rubin L, Yarden Y. *The basic biology of HER2*. Ann oncol, Vol.Supp 1, pp.S3-8
33. Gray MJ, Gallick GE. 2010. *The Role of Oncogene Activation in Tumor Progression. Mechanisms of Oncogenesis*. USA: Springer.
34. Grushko TA, Olopade OI. 2008. *Genetic markers in breast tumors with HEReditary predisposition. Principle of Molecular Oncology*. 3rd Edition. New Jersey : Humana Press.
35. Pluciennik, E, Kunsinska R, Potemski P, Kubiak R, Kordek R, et al 2006. WWOX-the FRA16D cancer gene: *Expression correlation with breast cancer progression and prognosis*: <http://dx.doi.org/10.1016/j.ejso.2005.11.002>
36. Boekhout, AH, Beijnan, HM. 2011. *Trastuzumab. The Oncologist*. 2011.16. p800-810
37. Carney et al, 2007. *HER-2/neu diagnostics in breast cancer. Breast Cancer Research*. 2007, **9**:207
38. Nielsen DL, Anderson M, Kamby C. 2009. *HER2 targeted therapy in breast cancer. Monoklonal antibodies and tyrosine kinase inhibitors. Cancer treatment reviews* Vol.35, pp 121-36.
39. Hudis, CA. 2007. *Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med*. **357** (1): 39–51.
40. Rita Nahta. 2012. *Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer*. International Scholarly Research Network, Vol. 2012, pp. 16

41. Goldhirsch A, Piccart-Gebhart MJ, Procter M, *et al.* HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. ESMO Congress Abstracts 2012
42. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, *et al.* Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* 2005;353: 1659–72.
43. Hasan TN, Grace BL, Shafi G, Syed R. 2013. rs11655505 (c.-2265 C/T) variant in *brca1* promoter is not associated with breast cancer risk in south india. *British Journal of Medicine & Medical Research* 3(1): 153-161
44. Ng EH, Gao F, Ji CY, Ho GH, Soo KC, 1997. Risk factors for breast cancer in Singaporean chinese women : the role of central obesity. *Cancer* 80(4) : 725-31.
45. Gill PG, Birrell SN, Luke CG, Roder DM, 2002. Tumor location and prognostic characteristics as determinants of survival of women with invasive breast cancer : South Australia hospital-based cancer registries, 1987-1998. *The Breast* 11:221-227.
46. Grosclaude P, Colonna M, Hedelin G, Tretarre B, Arveux P, Lesech ML, Raverdy N, Sauvage-Machelard M, 2001. Survival of women with breast cancer in France: variation with age, stage and treatment. *Breast Cancer Res and Treat* 70:137-143.
47. Brünner WN, Stephens RW, Dane K, 2000. *Control of Invasion and Metastasis*. Dalam :Harris JR, Lippmann ME, Morrow M, Osborne CK(eds).*Diseases of the Breast*. Second edition, Lippincott, Williams & Wilkins, Philadelphia : 367- 375.
48. Kastan MB and Skapek SX, 2001. *Molecular Biology of Cancer : The Cell Cycle* dalam De Vita VT, Hellman S, Rosenberg SA (eds): *Cancer. Principles&Practice of Oncology*. 6th edition, Lippincott Williams and Wilkins, Philadelphia: 91 -109
49. Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coebergh JWW. 2008. An overview of prognostic factors for long-term survivors of breast cancer. *Breast Cancer Res Treat* 107:309–330
50. Lakhani, S.R., Ellis. I.O., Schnitt, S.J., Tan, P.H., van de Vijver, M.J. WHO *classification of tumours*. Ed 4th. IARC. 2012
51. Leong A S-Y, Milios J, 1993. Comparison of antibodies to estrogen and progesterone receptors and the influence of microwave-antigen retrieval. *Appl. Immunohistochem* 1(4): 282-8.

52. Bringolf et al. *Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital*. Swiss Med Wkly. 2016;146:w14393
53. Cheang MCU, Chia SK, Voduc D, et al. 2009. *Ki67 index, HER2 status and prognosis of patients with luminal b breast cancer*. J Natl Cancer Inst;101(10): 736–50.
54. Vicci P et al. *Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis*. The Retroher study. Breast Cancer Res Treat (2014) 147:599–607
55. Rodrigues NA, Dillon D, Carter D, Pansat N, Haffty BG, 2003. *Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women*. Cancer 97 (6) :1393 -403. *Cancer J. Clin.*47:28-51.
56. Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ, 1998. *P53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer*. J Clin Oncol ;16(2) : 470-9.
57. Quiet CA, Ferguson DJ, Weichselbaum RP, Hellman S, 1996. *Natural history of node-positive breast cancer : The curability of small cancers with a limited number of positive nodes*. *J.Clin.Oncol* 14:3105-3111
58. Clark GM,2000. *Prognostic and Predictive Factors*. Dalam: Harris JR, Lippmann ME, Morrow M, Osborne CK(eds). *Diseases of the Breast* . Second edition, Lippincott, Williams&Wilkins, Philadelphia : 489-514.
59. Clark GM, 1996. *Prognostic and Predictive Factors*. Dalam : Harris Jr, Lippmann ME, Morrow M,Hellman S (eds). *Diseases of the Breast*. Philadelphia : Lippincott-Raven : 461-85
60. Slamoan et al. *Adjuvant Trastuzumab in HER2-Positive Breast Cancer*. N Engl J Med 2011;365: 1273-83.
61. Schnitt SJ and Guidi AJ, 2000. *Pathology of invasive breast cancer*. Dalam: Harris JR, Lippmann ME, Morrow M, Osborne CK(eds). *Diseases of the Breast*. Second edition, Lippincott, Williams&Wilkins, Philadelphia: 425 – 470.
62. Miremadi A and Pinder SE, 2002. *Pathology and classification of breast carcinoma*. *BCO*, 5:1-7.

63. Rouanet P, Pascal R, et al. *HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0*. Breast cancer: results from a French regional cohort. *Cancer Medicine* 2014; 3(1): 134–142
64. Peto PJ, Collins N, Barfoot R, et al. 1999. *Prevalence of brca1 and brca2 gene mutations in patients with early-onset breast cancer*. *J Natl Cancer Inst* 91(11): 943–9.
65. Schmitt FC, Ferreira MP, 1995. *MIB-1 is a suitable marker of proliferative activity in formalin-fixed, paraffin-embedded sections of breast cancer*. *Int. Jof. Surg. Pathol.* 2(4): 287-94.
66. Markiewski M, Domagala W, 1996. *Immunohistochemical assesment of proliferation rate of breast carcinoma using Ki-67, MIB-1 and anti-PCNA Antibodies*. *Pol J Pathol* 47(4):189-194. Masood S, 1995. *Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers*. *Surg Oncol Clin N Am* 4(4):601-632
67. Ricciardi, Giuseppina RR., Barbara Adamo, Antonio Leni, Luana Licata, Roberta Cardia et al. 2015. *Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients*. *PloS One* ; 10(6): e0128368, June 2015.
68. Pivot, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. *Lancet oncology*. 2013; 14; 741-48.
69. Harahap, WA, et al. 2017. *Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer*. *Asian Pasific Journal of Cancer Prevention*, Vol.18 : 1151-1156.